This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
EHA 2023
Presentations
Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #P1064
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced stage classical Hodgkin lymphoma: Updated efficacy and safety results from the single-arm phase 2 study
Brentuximab Vedotin | PTCL | Abstract #P1130
Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression: Initial efficacy and safety results from the phase 2 study (SGN35-032)